The Flixene Vascular Graft is a next-generation composite graft indicated for vascular access and arterial vascular reconstruction from Atrium Medical Corporation of Hudson, New Hampshire. The graft is built from a proprietary biomaterial film lamination process and offers superior kink and compression resistance. According to the manufacturer, the graft possesses excellent “burst” and “suture strength,” and is resistant to weeping fluid that is often observed with traditional vascular bypass grafts following implantation.
Becaue of the ability to access the graft immediately after implanting(as opposed to normal practice of allowing the PTFE to "incorporate" for 2-3 weeks before access), we have used the Flixene for situations where we would like to avoid a temporary dialysis catheter such as a person with autogenous fistula and aneurysms requiring interposition revision. For this situation interposition of The Flixene allows the uninterrupted use of the access followin revision. The proprietary film lamination permits immediate needle access and sealing of the graft.
Central venous catheter placement is associated with a significant incidence of central vein stenosis within the insersion site Internal Juglar and Brachiocephalic Arch region. Studies have demonstrated central venous thromboses in up to 30% of patients following central catheter placement. Additionally the infectious complications of central catheters are well documented.
The challenge for Atrium Medical is that with increasing pressue to pay for perfomance and best practice for fistula creation the placement of autogenous grafts is becoming less frequent
My fellow Americans , ask not what your country can do for you; ask what you can do for your country . My fellow citizens of the world ; ask not what America will do for you, but what together we can do for the freedom of man .
Posted by: New Balance 574 | October 13, 2010 at 08:27 PM